A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct
therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease.
Mesdopetam is taken for 84 days.